Evonik launches updated Biolys® product for animal feeds
- The new Biolys® provides higher concentration of L-lysine
- Lysine source with the lowest carbon footprint available on the feed additives market
- Available June 1 in existing pack sizes
Essen, Germany. In keeping with the tradition of supplying the market with innovative products and solutions to benefit its customers, Evonik will launch a new generation of Biolys®, a proven source of lysine for livestock feeds, on June 1.
The new Biolys® formulation contains 62.4 percent L-lysine (an 80 percent ratio to Lysine HCl) compared to the current version’s 60 percent L-lysine (a 77 percent ratio to Lysine HCl). The product also contains valuable components resulting from its fermentation process — additional nutrients and energy that further benefit livestock such as swine or poultry.
“The new Biolys® allows our customers to meet their animals’ requirements for the essential amino acid L-lysine even more efficiently. They can achieve the usual effect with less product”, says Dr. Martin Steffan, product manager Biolys® at Evonik Animal Nutrition. “This is fully in line with our strategy to meet growing global demand for high-quality animal protein for healthy human nutrition using a minimum of natural resources.”
Biolys® is produced by means of fermentation. Microorganisms convert dextrose, a sugar derived from corn, into L-lysine. The product contains L-lysine granulated with a nutritionally rich biomass. Since 2021, Evonik has managed to reduce the CO2 emissions from this production process by roughly 20 percent, leading to the lowest carbon footprint for lysine available on the market.
Biolys® is produced at Evonik’s sites in Castro, Paraná, Brazil, and Blair, Nebraska, USA, serving mainly the markets in the Americas, but also in the Middle East and in Africa. It will be available from June 1, 2023, in its traditional packaging versions.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €18.5 billion and an operating profit (adjusted EBITDA) of €2.49 billion in 2022. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 34,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €4.24 billion in 2022 with about 5,700 employees.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.